Search is Powered by Google
Follow us on:
Follow our health news on Twitter
Follow Our News on Facebook
Personalization
login | register
Lymphoma / Leukemia / Myeloma News

Survival Of Young Infants With Acute Lymphoblastic Leukaemia Increases With New Treatment Protocol

rate icon Editor's Choice
Main Category: Lymphoma / Leukemia / Myeloma
Also Included In: Pediatrics / Children's Health;  Clinical Trials / Drug Trials;  Cancer / Oncology
Article Date: 20 Jul 2007 - 0:00 PST

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:4 stars

4 (3 votes)

Health Professional:not yet rated

Article Opinions: 1 posts

Infants less than one year old with acute lymphoblastic leukaemia have increased survival with a new treatment protocol, compared to those on conventional regimes, according to a report in this week's medical journal The Lancet.

Acute lymphoblastic leukaemia (ALL) in babies under one year of age is rare and biologically different from ALL in older babies and children. Over the last 40 years the cure rate for ALL has improved from 10% to 80%, but not for infants less than twelve months' old, where current event-free survival (EFS) stands at around 17-45%.

Dr. Rob Pieters, Erasmus MC-Sophia Childrens' Hospital, Rotterdam, Netherlands, and team, carried out a study of 482 infants under one year of age - from 22 different countries. The babies were listed in risk-order following their peripheral blood response to a standard ALL 7-day predisone pre-treatment for ALL. They then received a hybrid treatment regime based on the standard treatment protocol for ALL, which incorporated some elements designed for treatment of AML (acute myeloid leukaemia).

After a three-year follow-up 58% of those who received the hybrid treatment were in complete remission, and at four years 47% had experienced EFS, compared to 17-45% EFS in previous studies of ALL. The researchers also reported that the hybrid treatment protocol did not produce more toxic effects than previous treatments. "Patients treated with our hybrid protocol, and especially those who responded poorly to prednisone, had higher EFS than most reported outcomes for treatment of infant ALL," said the authors.

"We believe that this hybrid treatment protocol will be used as the standard for continuing international collaborative studies that aim to further improve outcomes for acute lymphoblastic leukaemia in infants," the authors concluded.

"New Treatment Protocol Increases Survival Of Very Young Infants With Acute Lymphoblastic Leukaemia"
Dr. Rob Pieters et al
http://www.thelancet.com

Written by: Christian Nordqvist
Editor: Medical News Today
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today


Personalized Homepage Weekly Newsletters Daily News Alerts
Hemophilia Opioid Induced Constipation Pneumococcal Disease ADHD Anxiety Asthma Atrial Fibrillation Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Please fill in our survey

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
What Is Chemotherapy? What Are The Side Effects Of Chemotherapy?
22 Jul 2009
Chemotherapy is the use of chemicals (medication) to treat disease - more specifically, it usually refers to the destruction of cancer cells. However, chemotherapy also includes the use of antibiotics or other medications to treat any disease...


CML Therapy Side Effects image CML Therapy Side Effects

Even "targeted" therapy for chronic myeloid leukemia is not without side effects. Some, like low blood counts, are serious. Hear how one patient, along with her oncologist, Dr. Neil Shah of UCLA, managed the side effects of her CML treatment...

Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

View more videos...